Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity.

Abstract excerpt

Fentanyl and other synthetic opioids are the leading cause of drug-related deaths in the United States. mAbs that selectively target fentanyl and fentanyl analogues offer a promising strategy for treating both opioid-related overdoses and opioid use disorders. To increase the duration of efficacy of a candidate mAb against fentanyl, we selected three sets of mutations in the Fc region of an IgG1 anti-fentanyl mAb...

Topics

Join the communities discussing this publication.

• Analgesics, Opioid
• Fentanyl
• Half-Life
• Histocompatibility Antigens Class I
• Immunoglobulin Fc Fragments